@article{b8fe7a6551f64d28bc3e2432db73a61e,
title = "Telemedicine and cystic fibrosis: Do we still need face-to-face clinics?",
abstract = "There has been growing interest in telemedicine for cystic fibrosis over recent years based largely on convenience for patients and/or increasing the frequency of surveillance and early detection which, it is assumed, could improve treatment outcomes. During 2020, the covid-19 pandemic catalysed the pace of development of this field, as CF patients were presumed to be at high risk of infection. Most clinics adapted to digital platforms with provision of lung function monitoring and sample collection systems. Here, we present the views of multidisciplinary team members at a large paediatric CF centre on what has worked well and what requires further optimisation in the future. In response to the question posed, {\textquoteleft}Do we still need face to face clinics?{\textquoteright} our answer is {\textquoteleft}Yes, but not every time, and not for everyone{\textquoteright}.",
keywords = "Cystic fibrosis, Home monitoring, Lung function, Physiotherapy, Psychology, Remote care, Spirometry, Telehealth, Telemedicine",
author = "E. Dixon and S. Ollosson and H. Mattock",
note = "Funding Information: The authors wish to recognise contributions from the Royal Brompton & Harefield Hospitals Charity for assistance with equipment funding and patient travel during the coronavirus pandemic. Research at the site is supported by the Cystic Fibrosis Trust and by the National Institutes of Health Research through the Imperial Biomedical Research Centre, the Royal Brompton/NHLI Clinical Research Facility and a Senior Investigator Award (JCD). Prof. Jane Davies has performed clinical trial leadership roles, educational and/ or advisory activities for the following: Abbvie, Algipharma AS, Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Eloxx, Enterprise, Galapagos NV, ImevaX GmbH, Ionis, Nivalis Therapeutics, Inc. Novartis, ProQR Therapeutics III B.V. Proteostasis Therapeutics, INC. Pulmocide Raptor Pharmaceuticals, Inc, Vertex Pharmaceuticals. The other authors have no disclosures of interest. Funding Information: The authors wish to recognise contributions from the Royal Brompton & Harefield Hospitals Charity for assistance with equipment funding and patient travel during the coronavirus pandemic. Research at the site is supported by the Cystic Fibrosis Trust and by the National Institutes of Health Research through the Imperial Biomedical Research Centre, the Royal Brompton/NHLI Clinical Research Facility and a Senior Investigator Award (JCD). Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",
year = "2022",
month = jun,
day = "1",
doi = "10.1016/j.prrv.2021.05.002",
language = "English",
volume = "42",
pages = "23--28",
journal = "Paediatric Respiratory Reviews",
issn = "1526-0542",
publisher = "Elsevier",
}